Leveraging extensive experience in protein therapeutics toward the development of next generation and novel biologics.

The Pfenex Expression Technology platform is unique in its ability to express complex antibody derivatives and other engineered binding modalities. These complex modalities have the potential for greater specificity, improved side effect profiles and ultimately successful therapeutic outcomes making them the focus of current biopharmaceutical development. We believe that our focused discovery and development engine positions us well to be a leader in the space.

In pursuit of novel wholly owned product candidates, Pfenex has established a collaboration with a third-party technology platform company who is screening Pfenex selected and validated biological targets with its novel binding modality library in an effort to identify potential lead product candidates. Those candidates, PF91X, will be transferred to Pfenex and could become wholly owned product candidates developed by Pfenex.

Pfenex Expression Technology Platform Overview

Intellectual Property

Pfenex maintains a broad and comprehensive platform and product intellectual property portfolio with 24 U.S. issued patents as of December 2019 and additional in various stages of prosecution.